- Wheeler Bio has entered an agreement with MindImmune Therapeutics to provide process development and cGMP drug substance manufacturing services.
- The partnership will support the MITI-101 monoclonal antibody programme targeting neuroinflammation in Alzheimer’s disease.
Wheeler Bio, a U.S.-based contract development and biomanufacturing organisation (CDMO), has signed an agreement with MindImmune Therapeutics to provide integrated process development and cGMP drug substance manufacturing services. The work will be delivered through Wheeler’s ModularCMC™ platform, which focuses on antibody-based modalities.
The agreement supports MindImmune’s MITI-101 programme, a monoclonal antibody designed to block CD11c+ immune cell recruitment into the brain. This first-in-class approach aims to prevent the pathological effects of immune cell infiltration, a driver of neuroinflammation believed to underlie Alzheimer’s disease and other neurodegenerative disorders.
Wheeler Bio describes its ModularCMC platform as a way to accelerate the path from discovery to clinical study initiation, with speed, agility, and scalability. The CDMO highlights its scientific team’s experience across more than 1,400 unique molecules.
Patrick Lucy, President & CEO of Wheeler Bio, said: “We are thrilled to establish this partnership with MindImmune to advance this promising therapeutic focused on a disease where there is significant unmet medical need.”
MindImmune Therapeutics is focused on developing therapies to stop neuroinflammatory disease progression, preserve neuronal connections, and protect brain health, aiming to improve quality of life for people living with Alzheimer’s and related conditions.
